OASIS-5 showed fondaparinux (Arixtra) to be non-inferior in efficacy to enoxaparin (Lovenox) and to be associated with a decreased risk of bleeding in the treatment of unstable angina and NSTEMI. A new study in the American Heart Journal confirms these observations.
Fondaparinux has some unique risks but seems to cause less bleeding when used in the treatment of ACS. The findings cannot be extrapolated to the treatment VTE, in which higher doses of fondaparinux are used.
1 comment:
Pretty helpful info, lots of thanks for this article.
Post a Comment